18.50

0.71% 0.13

After Hours: 18.49 -0.01 -0.05%

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $18.50, with a volume of 1.88M. It is up +0.71% in the last 24 hours and up +12.67% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Previous Close:

$18.37

Open:

$18.17

24h Volume:

1.88M

Relative Volume:

0.83

Market Cap:

$2.82B

Revenue:

$205.22M

Net Income/Loss:

$-121.24M

P/E Ratio:

-22.72

EPS:

-0.8141

Net Cash Flow:

$-82.81M

1W Performance:

-0.27%

1M Performance:

+12.67%

6M Performance:

+77.20%

1Y Performance:

+135.37%

1-Day Range:

$17.98

$18.70

1-Week Range:

$17.65

$19.42

52-Week Range:

$6.255

$20.76

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1111)

Industry

Biotechnology (622)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

619

Twitter

@adaptivebiotech

Next Earnings Date

2025-02-11

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	18.50	2.80B	205.22M	-121.24M	-82.81M	-0.8141
VRTX Vertex Pharmaceuticals Inc	469.90	120.69B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.45	78.77B	14.34B	4.50B	3.88B	41.57
ARGX Argen X Se Adr	840.50	52.46B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	338.06	45.82B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	340.38	38.73B	4.98B	69.59M	525.67M	0.5197

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight
Sep-30-25	Initiated	Guggenheim	Buy
Jun-18-25	Initiated	Craig Hallum	Buy
Mar-21-25	Upgrade	Goldman	Neutral → Buy
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

Jan 30, 2026

Adaptive Biotechnologies Reports Strong Revenue Growth Amid Strategic Shift - AD HOC NEWS

Jan 30, 2026

Jan 27, 2026

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences - The Manila Times

Jan 27, 2026

Biotech using immune genetics schedules Feb. and March investor webcasts - Stock Titan

Jan 27, 2026

Jan 26, 2026

The Analyst Verdict: Adaptive Biotechnologies In The Eyes Of 4 Experts - Benzinga

Jan 26, 2026

Guggenheim Raises Price Target for ADPT to $21, Maintains Buy Ra - GuruFocus

Jan 26, 2026

Jan 22, 2026

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 - The Manila Times

Jan 22, 2026

Jan 16, 2026

First Week of March 20th Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq

Jan 16, 2026

Sumitomo Mitsui Trust Group Inc. Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat

Jan 16, 2026

Aug Selloffs: Will Adaptive Biotechnologies Corporation stock go up in YEARJuly 2025 Spike Watch & Comprehensive Market Scan Insights - baoquankhu1.vn

Jan 16, 2026

Jan 15, 2026

Adaptive Biotechnologies Insider Sold Shares Worth $1,411,131, According to a Recent SEC Filing - marketscreener.com

Jan 15, 2026

Adaptive Biotechnologies’ Lo Francis sells $1.4m in shares By Investing.com - Investing.com South Africa

Jan 15, 2026

Jan 14, 2026

Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 79,590 Shares of Stock - MarketBeat

Jan 14, 2026

Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong Recent Share Price Momentum - Yahoo Finance

Jan 14, 2026

Jan 13, 2026

Piper Sandler reiterates Overweight rating on Adeptus Biotechnologies stock By Investing.com - Investing.com Australia

Jan 13, 2026

What's Going On With Adaptive Biotechnologies Shares Tuesday? - Benzinga

Jan 13, 2026

Piper Sandler reiterates Overweight rating on Adeptus Biotechnologies stock - Investing.com

Jan 13, 2026